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Purpose 
The optimal strategy for revascularization in below-the-knee (BTK) chronic limb-threatening ischemia 
(CLTI) remains debatable. High restenosis rates of percutaneous transluminal angioplasty (PTA) 
often warrants re-intervention or amputations. Novel devices such as drug-eluting (paclitaxel) 
balloons (DEB), stents, and atherectomy devices- directional (HawkOne, SilverHawk, TurboHawk) 
™ or orbital (DiamondBack 360) ™ are used infrequently as therapy when BTK.  We aim to compare 
the rate of total re-occlusion between these interventions. 
 
Material & Methods 
A retrospective chart review of 97 patients who underwent BTK percutaneous intervention in 2015-
2020 at our hospital. Descriptive statistics were used to assess the distribution of variables; 
continuous variables (time to readmissions) were summarized as mean values with standard 
deviations, and categorical variables were summarized as counts and percentages. 
 
Results 
Out of the 97 patients, 73.4% met documented Rutherford category V-VI on initial admission, 53.6% 
patients were readmitted to our facility with Rutherford category IV-VI at 8 +/- 8 months from initial 
intervention, 79.7% were diabetic and 62.5% were hypertensive. Interventions performed on the 208 
arteries were plain balloon angioplasty 57.7%, DEB 2.9%, atherectomy with adjunctive PTA (A+PTA) 
28.8%, stent 8.7% and atherectomy with adjunctive stent (A+S) 2.9%.  Of the stents placed, 13 were 
bare-metal stent (BMS) and 11 drug-eluting (everolimus) stent (DES).  
Within 12 months from initial intervention, total re-occlusion post PTA occurred at 4 (+/-3) months, 
A+PTA 3.7 (+/-2) months, and stents 8 (+/-3) months (p= 0.015, F= 4.6). Comparing stents, 
restenosis was 53.8% in BMS versus 18.2% in DES (p= 0.09) at 6 (+/-3) months readmission. Re-
occlusion rates 30 months from initial intervention were 58.1% for uncoated balloons, 33.3% A+PTA, 
60% DEB, 50% stents and 50% A+S (p= 0.27). 22 patients were not readmitted again for any 
reason. Of the 17 patients who underwent major amputation (below or above the knee), 10 had 
triple-vessel involvement below the knee, 4 had osteomyelitis. Restoring straight-line flow in 





These preliminary data suggest superior short term (< 1-year) patency of stents over PTA and 
A+PTA, BTK. Re-occlusion in A+PTA may be lower than PTA alone. DES seems to have better 
patency than BMS. Further studies needed to compare clinical outcomes. 
 
